The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
The Genetic Evolution of Melanoma from Precursor Lesions
Open accessAbstract
BACKGROUND: The pathogenic mutations in melanoma have been largely catalogued; however, the order of their occurrence is not known. METHODS: We sequenced 293 cancer-relevant genes in 150 areas of 37 primary melanomas and their adjacent precursor lesions. The histopathological spectrum of these areas included unequivocally benign lesions, intermediate lesions, and intraepidermal or invasive melanomas. RESULTS: Precursor lesions were initiated by mutations of genes that are known to activate the mitogen-activated protein kinase pathway. Unequivocally benign lesions harbored BRAF V600E mutations exclusively, whereas those categorized as intermediate were enriched for NRAS mutations and additional driver mutations. A total of 77% of areas of intermediate lesions and melanomas in situ harbored TERT promoter mutations, a finding that indicates that these mutations are selected at an unexpectedly early stage of the neoplastic progression. Biallelic inactivation of CDKN2A emerged exclusively in invasive melanomas. PTEN and TP53 mutations were found only in advanced primary melanomas. The point-mutation burden increased from benign through intermediate lesions to melanoma, with a strong signature of the effects of ultraviolet radiation detectable at all evolutionary stages. Copy-number alterations became prevalent only in invasive melanomas. Tumor heterogeneity became apparent in the form of genetically distinct subpopulations as melanomas progressed. CONCLUSIONS: Our study defined the succession of genetic alterations during melanoma progression, showing distinct evolutionary trajectories for different melanoma subtypes. It identified an intermediate category of melanocytic neoplasia, characterized by the presence of more than one pathogenic genetic alteration and distinctive histopathological features. Finally, our study implicated ultraviolet radiation as a major factor in both the initiation and progression of melanoma. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Self-citationA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing
Talevich, E., Shain, A. H., Botton, T., & Bastian, B. C. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004873 · Cited by 2,094
Self-citationActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Huang, F. W., Hodis, E., Xu, M. J., Kryukov, G. V., Chin, L., & Garraway, L. A. (2013) · Science · doi:10.1126/science.1229259 · Cited by 1,816
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Van Raamsdonk, C. D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’Brien, J. M., Simpson, E. M., Barsh, G. S., & Bastian, B. C. (2009) · Nature · doi:10.1038/nature07586 · Cited by 1,623
Self-citationMutations in GNA11 in Uveal Melanoma
Van Raamsdonk, C. D., Griewank, K. G., Crosby, M. B., Garrido, M. C., Vemula, S., Wiesner, T., Obenauf, A. C., Wackernagel, W., Green, G., Bouvier, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000584 · Cited by 1,476
Self-citationExome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191
Cited by
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
“However, the Warburg Effect is thought to be an early event in oncogenesis that is an immediate consequence of an initial oncogenic mutation, such as that of KRAS in pancreatic cancer or BRAF in melanoma; thus, it occurs not only before cell invasion, but also in benign and early-stage lesions [45,46].”
BackgroundTumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Schadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., Stang, A., Roesch, A., & Ugurel, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31559-9 · Cited by 1,488
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
Application of Cell-free DNA Analysis to Cancer Treatment
Corcoran, R. B., & Chabner, B. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706174 · Cited by 950
Shain, A. H., & Bastian, B. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.37 · Cited by 896
Self-citationRoh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859
Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00821-8 · Cited by 746
Metastasis as an evolutionary process
Turajlic, S., & Swanton, C. (2016) · Science · doi:10.1126/science.aaf2784 · Cited by 661
Burstein, H. J., Krilov, L., Aragon-Ching, J. B., Baxter, N. N., Chiorean, E. G., Chow, W. A., De Groot, J. F., Devine, S. M., DuBois, S. G., El-Deiry, W. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5292 · Cited by 601
Cutaneous melanoma: From pathogenesis to therapy (Review)
Leonardi, G., Falzone, L., Salemi, R., Zangh�, A., Spandidos, D., Mccubrey, J., Candido, S., & Libra, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4287 · Cited by 588
Deep Visual Proteomics defines single-cell identity and heterogeneity
Mund, A., Coscia, F., Kriston, A., Hollandi, R., Kovács, F., Brunner, A.-D., Migh, E., Schweizer, L., Santos, A., Bzorek, M., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01302-5 · Cited by 562
Rozenblatt-Rosen, O., Regev, A., Oberdoerffer, P., Nawy, T., Hupalowska, A., Rood, J. E., Ashenberg, O., Cerami, E., Coffey, R. J., Demir, E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.053 · Cited by 564
An evolutionary perspective on field cancerization
Curtius, K., Wright, N. A., & Graham, T. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.102 · Cited by 509
Elder, D. E., Bastian, B. C., Cree, I. A., Massi, D., & Scolyer, R. A. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0561-ra · Cited by 502
Self-citationDummer, R., Schadendorf, D., Ascierto, P. A., Arance, A., Dutriaux, C., Di Giacomo, A. M., Rutkowski, P., Del Vecchio, M., Gutzmer, R., Mandala, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30180-8 · Cited by 499
Self-citationKwok, G., Yau, T. C. C., Chiu, J. W., Tse, E., & Kwong, Y.-L. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1199310 · Cited by 498
Elmore, J. G., Barnhill, R. L., Elder, D. E., Longton, G. M., Pepe, M. S., Reisch, L. M., Carney, P. A., Titus, L. J., Nelson, H. D., Onega, T., et al. (2017) · BMJ · doi:10.1136/bmj.j2813 · Cited by 436
Cheng, L., Lopez-Beltran, A., Massari, F., MacLennan, G. T., & Montironi, R. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.104 · Cited by 407
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 399
Regulation of human telomerase in homeostasis and disease
Roake, C. M., & Artandi, S. E. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0234-z · Cited by 346
Thrane, K., Eriksson, H., Maaskola, J., Hansson, J., & Lundeberg, J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0747 · Cited by 337
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Basset-Seguin, N., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.008 · Cited by 329
Understanding TERT Promoter Mutations: A Common Path to Immortality
Bell, R. J. A., Rube, H. T., Xavier-Magalhães, A., Costa, B. M., Mancini, A., Song, J. S., & Costello, J. F. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0003 · Cited by 307
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
Accumulation of genetic and epigenetic alterations in normal cells and cancer risk
Takeshima, H., & Ushijima, T. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0079-0 · Cited by 300
Intratumor and Intertumor Heterogeneity in Melanoma
Grzywa, T. M., Paskal, W., & Włodarski, P. K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.09.007 · Cited by 299
Chiba, K., Lorbeer, F. K., Shain, A. H., McSwiggen, D. T., Schruf, E., Oh, A., Ryu, J., Darzacq, X., Bastian, B. C., & Hockemeyer, D. (2017) · Science · doi:10.1126/science.aao0535 · Cited by 276
Self-citationMelanocortin 1 Receptor: Structure, Function, and Regulation
Wolf Horrell, E. M., Boulanger, M. C., & D’Orazio, J. A. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00095 · Cited by 272
Zebrafish patient avatars in cancer biology and precision cancer therapy
Fazio, M., Ablain, J., Chuan, Y., Langenau, D. M., & Zon, L. I. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0252-3 · Cited by 257
Targeting telomerase for cancer therapy
Guterres, A. N., & Villanueva, J. (2020) · Oncogene · doi:10.1038/s41388-020-01405-w · Cited by 256
Clonal expansion in non-cancer tissues
Kakiuchi, N., & Ogawa, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00335-3 · Cited by 252
Mechanisms of UV-induced mutations and skin cancer
Pfeifer, G. P. (2020) · Genome Instability & Disease · doi:10.1007/s42764-020-00009-8 · Cited by 237
Wang, J., Perry, C. J., Meeth, K., Thakral, D., Damsky, W., Micevic, G., Kaech, S., Blenman, K., & Bosenberg, M. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12591 · Cited by 199
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., Mao, X., De Macedo, M. P., Chen, J., Song, X., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0013-8 · Cited by 166
Liang, G., Liu, M., Wang, Q., Shen, Y., Mei, H., Li, D., & Liu, W. (2017) · Oncotarget · doi:10.18632/oncotarget.15324 · Cited by 78
“Some genetic alterations on signaling molecules such as CDKN2A, PDK1, PTEN, and AKT have also been associated with the pathogenesis of melanoma [4].”
BackgroundCDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
Betti, M., Aspesi, A., Biasi, A., Casalone, E., Ferrante, D., Ogliara, P., Gironi, L. C., Giorgione, R., Farinelli, P., Grosso, F., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.011 · Cited by 78
Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma
Melamed, R. D., Aydin, I. T., Rajan, G. S., Phelps, R., Silvers, D. N., Emmett, K. J., Brunner, G., Rabadan, R., & Celebi, J. T. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.11.017 · Cited by 58
L’Hôte, V., Courbeyrette, R., Pinna, G., Cintrat, J., Le Pavec, G., Delaunay‐Moisan, A., Mann, C., & Thuret, J. (2021) · Aging Cell · doi:10.1111/acel.13447 · Cited by 37
Goh, C. J. H., Wong, J. H., El Farran, C., Tan, B. X., Coffill, C. R., Loh, Y.-H., Lane, D., & Arumugam, P. (2021) · G3 Genes|Genomes|Genetics · doi:10.1093/g3journal/jkaa069 · Cited by 20
Differentiation States of Phenotypic Transition of Melanoma Cells Are Revealed by 3D Cell Cultures
Fontana, F., Sommariva, M., Anselmi, M., Bianchi, F., Limonta, P., & Gagliano, N. (2024) · Cells · doi:10.3390/cells13020181 · Cited by 11
Gambichler, T., Rohrmoser, E. ‐., Horny, K., Sucker, A., Schadendorf, D., Skrygan, M., Susok, L., Stücker, M., & Becker, J. C. (2022) · Clinical and Experimental Dermatology · doi:10.1111/ced.14951 · Cited by 4
Impact of particulate matter exposure on melanoma risk: A multicentre case–control study
Bellinato, F., Adami, G., Reatini, M. A., Cattani, G., Cannizzaro, M. V., Del Regno, L., Peris, K., Gisondi, P., & Girolomoni, G. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20539 · Cited by 3
Metadata
- Authors
- Shain, A. H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., Dummer, R., North, J., Pincus, L., Ruben, B., Rickaby, W., D’Arrigo, C., Robson, A., & Bastian, B. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-12
- Volume
- 373
- Issue
- 20
- Pages
- 1926-1936
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2220812108
- Cited by
- 1,065
- References
- 33
- FWCI
- 40.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.